<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ALFUZOSIN</span><br/>(al-fuz'o-sin)<br/><span class="topboxtradename">UroXatral, </span><span class="topboxtradename">Xatral <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification"> alpha-adrenergic antagonist (blocking agent, sympatholytic)</span><br/><b>Prototype: </b>Prazosin<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg extended-release tablet</p>
<h1><a name="action">Actions</a></h1>
<p>Alfuzosin is a short-acting, selective antagonist at alpha-1 receptors with a low incidence of hypotension and sexual dysfunction
         at therapeutic doses. Alpha-1 receptors cause contraction of smooth muscle in the prostate, prostatic capsule, prostatic urethra,
         bladder base, and bladder neck. Both alpha-1a (70%) and alpha-1b receptors exist in the prostate.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Blockade of alpha-1 receptors by alfuzosin causes smooth muscles in the bladder neck and prostate to relax, thereby reducing
         pressure on the urethra and improving urine flow rate. This results in a reduction in BPH symptoms.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of symptomatic benign prostatic hypertrophy (BPH).</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to alfuzosin; lactation; severe hepatic insufficiency; concurrent treatment with potent CYP3A4 inhibitors
         (e.g., ketoconazole, itraconazole, and ritonavir).
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category B); coronary artery disease; hepatic disease; dizziness, light-headedness, orthostatic hypotension.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Benign Prostatic Hypertrophy</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 10 mg q.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give immediately after same meal each day.</li>
<li>Ensure that extended-release tablet is not crushed or chewed. It must be swallowed whole.</li>
<li>Store at 15°30° C (59°86° F). Protect from light and moisture.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Fatigue, pain. <span class="typehead">CNS:</span> Dizziness, headache. <span class="typehead">GI:</span> Abdominal pain, dyspepsia, constipation, nausea. <span class="typehead">Respiratory:</span> Upper respiratory infection, bronchitis, sinusitis, pharyngitis. <span class="typehead">Urogenital:</span> Impotence, priapism. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Increased risk of hypotension with other <span class="classification">antihypertensive agents</span>; <b>ketoconazole, itraconazole,</b>
<span class="classification">protease inhibitors</span> may increase alfuzosin levels and toxicity. <b>Sildenafil,</b>
<b>vardenafil,</b> and <b>tadalafil </b>may enhance hypotensive effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 49% absorbed when taken with food. <span class="typehead">Peak:</span> 8 h. <span class="typehead">Metabolism:</span> Metabolized in liver by CYP3A4. <span class="typehead">Elimination:</span> 69% excreted in feces, 24% excreted in urine. <span class="typehead">Half-Life:</span> 10 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor CV status and BP, especially if on concurrent treatment with antihypertensive drugs or inhibitors of CYP3A4. See INTERACTIONS.</li>
<li>Check postural vital signs to evaluate for orthostatic hypotension within a few hours following administration.</li>
<li>Withhold drug and report new or worsening angina to physician.</li>
<li>Lab tests: Baseline and periodic LFTs.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Inform physician about all other prescription, nonprescription, or herbal drugs being taken.</li>
<li>Make position changes slowly to minimize dizziness.</li>
<li>Do not drive or engage in other hazardous activities until reaction to drug is known.</li>
<li>Moderate or eliminate grapefruit juice consumption while on this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>